DEFA14A ·Filed Mar 23, 2026
Proxy solicitation materials
Actionable Insight • Neutral
Monitor for the full proxy statement which may contain details about director elections, executive compensation, or shareholder proposals
HALO drugs
HALO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60Entry
$62.04
T+0 close · Mar 23, 2026 · via day close
Latest settled
+10.49%
T+60 · $68.55
Vs SPY
−3.83%
α at T+60
Horizons
All settled
through T+60
- T+0 · Mar 24 $62.04entry
- T+1 · 8mo ago +1.93%α +1.37% · $63.24
- T+5 · 8mo ago +4.17%α +4.60% · $64.63
- T+20 · 7mo ago +10.25%α +1.35% · $68.40
- T+60 · 5mo ago +10.49%α −3.83% · $68.55
Price Chart
REPLAYWatch the reaction play outLoading chart...
How similar events traded
Executive Summary
Analysis based on filing metadata only, document content was unavailable
Key Facts
- Filing is a DEFA14A (Definitive Additional Materials) for a proxy statement
- Filed by Halozyme Therapeutics, Inc. (HALO)
- No financial data or specific event details available in provided documents
Financial Impact
No financial impact data available
Risk Factors
- Lack of complete information prevents assessment of potential market impact
- Proxy statements may contain important governance information that could affect investor sentiment
Market Snapshot
Exchange
Nasdaq
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001159036-26-000042 |
| Document: 0001159036-26-000042-index-headers.html | 0001159036-26-000042 |
| Document: 0001159036-26-000042-index.html | 0001159036-26-000042 |
| Document: 0001159036-26-000042.txt | 0001159036-26-000042 |
Track record
15 reports on HALO
1 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +17.70% at T+20 after the Oct 15, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 9, 20268d ago PTAB Trial Bearish 6/10 Entry $102.98 Now $96.50 +6.29% settles Nov 17
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $124.54 to $131.18 Now $96.50 −22.51% ▲ +5.33% +4.62% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $124.83 to $128.50 Now $96.50 −22.69% ▲ +2.94% +3.38% vs SPY
- Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
- Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
- Sep 18, 20268w ago 8-K Mixed 6/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
- Sep 17, 20268w ago Insider Cluster Neutral 2/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $106.12 to $106.92 Now $96.50 −9.07% ▲ +0.75% −0.36% vs SPY
Showing 10 of 15
US Market Status
Market Closed · Opens in 7h 9m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers